Drug Interactions between dexamethasone and nirogacestat
This report displays the potential drug interactions for the following 2 drugs:
- dexamethasone
- nirogacestat
Interactions between your drugs
dexAMETHasone nirogacestat
Applies to: dexamethasone and nirogacestat
GENERALLY AVOID: Coadministration with moderate to potent CYP450 3A4 inducers may significantly decrease the plasma concentration and pharmacologic effects of nirogacestat, which is primarily metabolized by the isoenzyme. Coadministration of multiple doses of nirogacestat (150 mg twice daily) with the potent CYP450 3A4 inducer rifampin is predicted to decrease the systemic exposure (AUC) of nirogacestat by 85%. In addition, administration of multiple doses of nirogacestat (150 mg twice daily) with the moderate CYP450 3A4 inducer efavirenz is predicted to decrease the AUC of nirogacestat by 67%. Reduced therapeutic efficacy of nirogacestat may occur.
MANAGEMENT: According to the manufacturer, concomitant use of nirogacestat with moderate to potent CYP450 3A4 inducers should be avoided.
References (1)
- (2023) "Product Information. Ogsiveo (nirogacestat)." SpringWorks Therapeutics, Inc.
Drug and food interactions
nirogacestat food
Applies to: nirogacestat
GENERALLY AVOID: Grapefruit, grapefruit juice, Seville oranges, and starfruit may significantly increase the plasma concentrations and pharmacologic effects of nirogacestat. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in these fruits. Coadministration of multiple doses of nirogacestat (150 mg twice daily) with the moderate CYP450 3A4 inhibitors erythromycin and fluconazole are predicted to increase the AUC of nirogacestat by 2.73-fold and 3.18-fold, respectively. The interaction has not been studied with grapefruit, Seville oranges, or starfruit. In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition. Increased systemic exposure to nirogacestat may increase the risk of adverse effects including diarrhea, ovarian toxicity, hepatotoxicity, electrolyte abnormalities, and non-melanoma skin cancers.
MANAGEMENT: Patients treated with nirogacestat should avoid consumption of grapefruit, grapefruit juice, Seville oranges, starfruit, or any supplement containing grapefruit.
References (1)
- (2023) "Product Information. Ogsiveo (nirogacestat)." SpringWorks Therapeutics, Inc.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.